55 research outputs found
Native American Trauma and the Possibility of Healing in Louise Erdrich’s Love Medicine (1993).
A lo largo de la historia universal, se han sucedido una serie de invasiones y conquistas que han tenido consecuencias devastadoras en los grupos Nativos que habitaban esos lugares. En el caso Estados Unidos, desde la llegada de Cristóbal Colón en 1492, los europeos quisieron dominar el país y ejercieron una dura represión contra los grupos de Indígenas que se encontraron al establecerse en el territorio. Estos se oponían a las duras medidas que los recién llegados exigían e iban en contra de sus tradiciones. Esto originó una serie de enfrentamientos violentos que desembocaron en experiencias traumáticas y heridas que se pasaron de generación en generación. Louise Erdrich es una famosa escritora de Minnesota que, en su novela más reconocida, Love Medicine (1984), cuenta la historia de dos familias Nativas y todas las adversidades y desencuentros que sufren. La novela presenta una estructura muy peculiar por la cantidad de perspectivas sobre los eventos que les ocurren a los personajes y la interpretación que requieren. El foco principal de mi trabajo por un lado es analizar el doble trauma al que Henry Lamartine tiene que hacer frente. Es un soldado que vuelve de la Guerra de Vietnam, sufre estrés post-traumático y no consigue readaptarse a la vida en Norte América. Además, es un Nativo en la sociedad americana, y tiene profundas heridas que ha heredado de generaciones anteriores. Por el otro, Liphsa Morrisey consigue superar ese trauma Nativo que afecta a su comunidad de manera colectiva porque arroja un rayo de luz en esa sociedad puesto que demuestra que la evolución y el cambio es posible. Para ello, es relevante adentrarse en el marco teórico del trauma para saber cómo una experiencia traumática afecta a la mente y a la percepción de la realidad y analizar específicamente el trauma Nativo en Norte América. Seguidamente, se analizará la estructura de la novela, el capítulo en el que Henry se asienta cuando vuelve de Vietnam, y la relación que guarda este último con otros dos. Principalmente con el último de la novela donde se observa esa posibilidad de cambio y evolución en la comunidad Nativa puesto que no todos los finales tienen que ser como el de Henry.<br /
Spontaneous twin anemia polycythemia sequence: diagnosis, management, and outcome in an international cohort of 249 cases
Transfusió intrauterina; Cirurgia làser; Seqüència anemia-policitemia bessonaIntrauterine transfusion; Laser surgery; Twin anemia polycythemia sequenceTransfusión intrauterina; Cirugía láser; Secuencia anemia-policitemia gemelarBackground
Twin anemia polycythemia sequence is a chronic form of unbalanced fetofetal transfusion through minuscule placental anastomoses in monochorionic twins, leading to anemia in the donor and polycythemia in the recipient. Owing to the low incidence of twin anemia polycythemia sequence, data on diagnosis, management, and outcome are limited.
Objective
This study aimed to investigate the diagnosis, management, and outcome in a large international cohort of spontaneous twin anemia polycythemia sequence.
Study Design
Data from the international twin anemia polycythemia sequence registry, retrospectively collected between 2014 and 2019, were used for this study. A total of 17 fetal therapy centers contributed to the data collection. The primary outcomes were perinatal mortality and severe neonatal morbidity. Secondary outcomes included a risk factor analysis for perinatal mortality and severe neonatal morbidity.
Results
A total of 249 cases of spontaneous twin anemia polycythemia sequence were included in this study, 219 (88%) of which were diagnosed antenatally and 30 (12%) postnatally. Twin anemia polycythemia sequence was diagnosed antenatally at a median gestational age of 23.7 weeks (interquartile range, 9.7–28.8; range, 15.1–35.3). Antenatal management included laser surgery in 39% (86 of 219), expectant management in 23% (51 of 219), delivery in 16% (34 of 219), intrauterine transfusion (with partial exchange transfusion) in 12% (26 of 219), selective feticide in 8% (18 of 219), and termination of pregnancy in 1% (3 of 219) of cases. Perinatal mortality rate was 15% (72 of 493) for the total group, 22% (54 of 243) for donors, and 7% (18 of 242) for recipients ( P <.001). Severe neonatal morbidity occurred in 33% (141 of 432) of twins with twin anemia polycythemia sequence and was similar for donors (32%; 63 of 196) and recipients (33%; 75 of 228) ( P =.628). Independent risk factors for spontaneous perinatal mortality were donor status (odds ratio, 3.8; 95% confidence interval, 1.9–7.5; P <.001), antenatal twin anemia polycythemia sequence stage (odds ratio, 6.3; 95% confidence interval, 1.4–27.8; P =.016 [stage 2]; odds ratio, 9.6; 95% confidence interval, 2.1–45.5; P =.005 [stage 3]; odds ratio, 20.9; 95% confidence interval, 3.0–146.4; P =.002 [stage 4]), and gestational age at birth (odds ratio, 0.8; 95% confidence interval, 0.7–0.9; P =.001). Independent risk factors for severe neonatal morbidity were antenatal twin anemia polycythemia sequence stage 4 (odds ratio, 7.9; 95% confidence interval, 1.4–43.3; P =.018) and gestational age at birth (odds ratio, 1.7; 95% confidence interval, 1.5–2.1, P <.001).
Conclusion
Spontaneous twin anemia polycythemia sequence can develop at any time in pregnancy from the beginning of the second trimester to the end of the third trimester. Management for twin anemia polycythemia sequence varies considerably, with laser surgery being the most frequent intervention. Perinatal mortality and severe neonatal morbidity were high, the former especially so in the donor twins
Antiurolithic activity of Berberis trifoliate extract on induced urolithiasis in rats by zinc disc implantation
Background: In clinical therapy, there is no satisfactory drug available for treatment of urolithiasis, especially for the prevention of their recurrence. The aim of this work was to evaluate in vivo antiurolithic activity of methanolic extract of Berberis trifoliata leaves.Material and methods: Urolithiasis was induced in Wistar rats by zinc disc implantation in urinary bladder. Upon postsurgical recovery, different doses of the methanolic extract of B. trifoliata leaves (50, 100 and 150 mg/kg body weight) were administered orally to zinc disc implanted rats for a period of 20 days. Antiurolithiatic activity was evaluated by measuring the difference between the weight of the implanted zinc discs at the time of implantation and the final weight of the dried calculi taken out from the bladder at the end of the 20 days period of treatment.Results: Extract of B. trifoliata significantly reduced calculi deposition around the implanted zinc disc at all doses (50, 100, and 150 mg/kg).Conclusion: Treatment with methanolic extract of B. trifoliata is useful agent against the kidney stone formation.Keywords: Antiurolithic, Berberis trifoliata, urolithiasis, zinc disc implantation
Fetal abdominal cysts: Predicting adverse outcomes
Abdominal; Cyst; PerinatalAbdominal; Quist; PerinatalAbdominal; Quiste; PerinatalIntroduction
The primary aim of the study was to identify risk factors associated with fetal or neonatal loss, neonatal morbidity, and the need for surgery in fetuses diagnosed with an abdominal cyst. The secondary aim was to compare the characteristics of the cyst according to trimester at diagnosis.
Material and methods
This was an observational retrospective study performed at Vall d'Hebron University Hospital. The study included pregnant women aged 18 years or older with diagnosis of a fetal abdominal cyst from 2008 to 2021.
Results
A total of 82 women with a median gestational age of 31+1 weeks (12+0–39+4) were included in the analysis. Seven (8.5%) cases were diagnosed in the first trimester, 28 (34.1%) in the second trimester, and 47 (57.3%) in the third trimester. Fetal or neonatal loss occurred in 10 (12.2%) cases; significant predictors were diagnosis in the first trimester (OR 36.67, 95% CI: 4.89–274.79), male gender (OR 4.75, 95% CI: 1.13–19.9), and associated abnormalities (OR 15.2, 95% CI: 2.92–79.19). A total of 10 of 75 (13.3%) neonates showed at least one neonatal complication, and the only predictor was occurrence of associated abnormalities (OR 7.36, 95% CI: 1.78–30.51). A total of 16 of 75 (21.3%) neonates required postnatal surgery, and the predictors were second-trimester diagnosis (OR 3.92, 95% CI: 1.23–12.51), associated abnormalities (OR 3.81, 95% CI: 1.15–12.64), and bowel location (OR 10.0, 95% CI: 1.48–67.55).
Conclusions
Factors associated with adverse outcomes in fetuses diagnosed with abdominal cysts are first-trimester diagnosis and associated abnormalities. Cysts detected in the second trimester and those of intestinal origin are more likely to require surgery
Gestational age-based reference ranges for cervical length and preterm birth prediction in triplet pregnancies: an observational retrospective study
Cervical length; Preterm delivery; Triplet pregnancyLongitud cervical; Parto prematuro; Embarazo de trillizosLongitud cervical; Part prematur; Embaràs de trillissosObjectives
To develop gestational age-based reference ranges for cervical length in triplet pregnancies. The secondary objective was to assess the performance of cervical length measured between 18 and 20 + 6 days for the prediction of preterm delivery before 28 and 32 weeks, respectively.
Methods
Observational retrospective study of triplet pregnancies in three Spanish tertiary-care hospitals between 2001 and 2019. Cervical length measurements were consecutively obtained between 15 and 34 weeks of gestation. Pregnancies undergoing multifetal reduction or fetal surgery were excluded.
Results
Two hundred and six triplet pregnancies were included in the final analysis. There was a quadratic decrease in cervical length with gestational age. The median and fifth centiles for cervical length at 20 weeks were 35 and 13 mm. In the prediction of preterm birth < 28 weeks, for a false positive rate of 5%, and 10%, the detection rates were 40.9%, and 40.9%, respectively, and the prediction of preterm birth < 32 weeks, 22.0% and 26.0%, respectively.
Conclusions
In triplet pregnancies, cervical length decreases with gestational age. The performance of cervical length at 18–20 + 6 in screening for preterm birth before 28 and 32 weeks is poor
Reference values for interleukin-6 in the amniotic fluid of asymptomatic pregnant women
Amniocentesis; Interleukin-6; Intra-amniotic inflammationAmniocentesi; Interleucina-6; Inflamació intraamniòticaAmniocentesis; Interleucina-6; Inflamación intraamnióticaIntroduction
Nowadays, proinflammatory factors are considered to play an important role in the pathophysiology of threatened preterm labor or chorioamnionitis. The aim of this study was to establish the normal reference range for interleukin-6 (IL-6) levels in the amniotic fluid and to identify factors which may alter this value.
Material and methods
Prospective study in a tertiary-level center including asymptomatic pregnant women undergoing amniocentesis for genetic studies from October 2016 to September 2019. IL-6 measurements in amniotic fluid were performed using a fluorescence immunoassay with microfluidic technology (ELLA Proteinsimple, Bio Techne). Maternal history and pregnancy data were also recorded.
Results
This study included 140 pregnant women. Of those, women who underwent termination of pregnancy were excluded. Therefore, a total of 98 pregnancies were included in the final statistical analysis. The mean gestational age was 21.86 weeks (range: 15–38.7) at the time of amniocentesis, and 38.6 weeks (range: 30.9–41.4) at delivery. No cases of chorioamnionitis were reported. The log10 IL-6 values follow a normal distribution (W = 0.990, p = 0.692).
The median, and the 5th, 10th, 90th, and 95th percentiles for IL-6 levels were 573, 105, 130, 1645, and 2260 pg/mL, respectively. The log10 IL-6 values were not affected by gestational age (p = 0.395), maternal age (p = 0.376), body mass index (p = 0.551), ethnicity (p = 0.467), smoking status (p = 0.933), parity (p = 0.557), method of conception (p = 0.322), or diabetes mellitus (p = 0.381).
Conclusions
The log10 IL-6 values follow a normal distribution. IL-6 values are independent of gestational age, maternal age, body mass index, ethnicity, smoking status, parity and method of conception. Our study provides a normal reference range for IL-6 levels in the amniotic fluid that can be used in future studies. We also observed that normal IL-6 values were higher in the amniotic fluid than in serum.Some of the authors are members of the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability ERN-ITHACA (EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516)
ANTIUROLITHIC ACTIVITY OF BERBERIS TRIFOLIATA EXTRACT ON INDUCED UROLITHIASIS IN RATS BY ZINC DISC IMPLANTATION
Background: In clinical therapy, there is no satisfactory drug available for treatment of urolithiasis, especially for the prevention of their recurrence. The aim of this work was to evaluate in vivo antiurolithic activity of methanolic extract of Berberis trifoliata leaves.
Material and methods: Urolithiasis was induced in Wistar rats by zinc disc implantation in urinary bladder. Upon postsurgical recovery, different doses of the methanolic extract of B. trifoliata leaves (50, 100 and 150 mg/kg body weight) were administered orally to zinc disc implanted rats for a period of 20 days. Antiurolithiatic activity was evaluated by measuring the difference between the weight of the implanted zinc discs at the time of implantation and the final weight of the dried calculi taken out from the bladder at the end of the 20 days period of treatment.
Results: Extract of B. trifoliata significantly reduced calculi deposition around the implanted zinc disc at all doses (50, 100, and 150 mg/kg).
Conclusion: Treatment with methanolic extract of B. trifoliata is useful agent against the kidney stone formation
Multicenter prospective clinical study to evaluate children short-term neurodevelopmental outcome in congenital heart disease (children NEURO-HEART): study protocol
Congenital heart disease; Neurodevelopment; Predictive markersCardiopatía congénita; Desarrollo neurológico; Marcadores predictivosCardiopaties congènites; Neurodesenvolupament; Marcadors predictiusBackground: Congenital heart disease (CHD) is the most prevalent congenital malformation affecting 1 in 100 newborns. While advances in early diagnosis and postnatal management have increased survival in CHD children, worrying long-term outcomes, particularly neurodevelopmental disability, have emerged as a key prognostic factor in the counseling of these pregnancies. Methods: Eligible participants are women presenting at 20 to < 37 weeks of gestation carrying a fetus with CHD. Maternal/neonatal recordings are performed at regular intervals, from the fetal period to 24 months of age, and include: placental and fetal hemodynamics, fetal brain magnetic resonance imaging (MRI), functional echocardiography,
cerebral oxymetry, electroencephalography and serum neurological and cardiac biomarkers. Neurodevelopmental assessment is planned at 12 months of age using the ages and stages questionnaire (ASQ) and at 24months of age with the Bayley-III test. Target recruitment is at least 150 cases classified in three groups according to three main severe CHD groups: transposition of great arteries (TGA), Tetralogy of Fallot (TOF) and Left Ventricular Outflow Tract Obstruction (LVOTO). Discussion: The results of NEURO-HEART study will provide themost comprehensive knowledge until date of children’s neurologic prognosis in CHD and will have the potential for developing future clinical decisive tools and improving preventive strategies in CHD.RETICS funded by the PN 2018-2021 (Spain), ISCIII- Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (FEDER), reference RD16/002
Early-Stage Breast Cancer Detection in Breast Milk
Breast cancer; Breast milkCáncer de mama; Leche maternaCàncer de mama; Llet maternaBreast cancer occurring during pregnancy (PrBC) and postpartum (PPBC) is usually diagnosed at more advanced stages compared with other breast cancer, worsening its prognosis. PPBC is particularly aggressive, with increased metastatic risk and mortality. Thus, effective screening methods to detect early PrBC and PPBC are needed. We report for the first time that cell-free tumor DNA (ctDNA) is present in breast milk (BM) collected from patients with breast cancer. Analysis of ctDNA from BM detects tumor variants in 87% of the cases by droplet digital PCR, while variants remain undetected in 92% of matched plasma samples. Retrospective next-generation sequencing analysis in BM ctDNA recapitulates tumor variants, with an overall clinical sensitivity of 71.4% and specificity of 100%. In two cases, ctDNA was detectable in BM collected 18 and 6 months prior to standard diagnosis. Our results open up the potential use of BM as a new source for liquid biopsy for PPBC detection.
Significance:
For the first time, we show that BM obtained from patients with breast cancer carries ctDNA, surpassing plasma-based liquid biopsy for detection and molecular profiling of early-stage breast cancer, even prior to diagnosis by image.We thank the patients who participated in the study and donated samples for analysis for their generous contribution, with particular thanks to the first patient, Maite, and her daughter Àneu, who inspired us to initiate this study (oral consent to name the patient and her daughter was provided by the patient, and her legal partner provided written consent after patient's exitus). We are grateful to Javier Carmona for his valuable contributions and support in the manuscript's conceptualization, preparation, and revision. VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support of this research. The authors from VHIO acknowledge the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033). This research is financially supported by the “El paseíco de la mama” Foundation. C. Saura was the recipient of a II FERO-GHD grant from the FERO Foundation (FERO/5086), a Junior Clinical award from the Spanish Association Against Cancer Foundation (FAECC; CLJUN212026ORTI), and a SEOM-Daiichi Sankyo grant for its support on the Breast Cancer Research Projects 2021 (SEOM/FECMA2022) and received funding from the Department of Health (Generalitat de Catalunya SLT008/18/00198) and from the Instituto de Salud Carlos III (ISCIII) and Fondo Europeo de Desarrollo Regional (FEDER), cofunded by the European Union (PI21/01020). C. Ortiz was the recipient of a Junior Clinician award from the FAECC (CLJUN212026ORTI) and a SEOM-Daiichi Sankyo grant for its support on the Breast Cancer Research Projects 2021 (SEOM/FECMA2022), and received funding from the Department of Health (Generalitat de Catalunya SLT008/18/00198). N. Bayó-Puxan received funding from the Department of Health (Generalitat de Catalunya SLT008/18/00205), MCIN/AEI/10.13039/501100011033 (GPE2022-001029) and MCIN/AEI/10.130.39/501100011033, and the European Union “Next GenerationEU/PRTR” (ECT2020-000827). J.M. Miquel received funding from the Department of Health (Generalitat de Catalunya SLT008/18/00205), MCIN/AEI/10.130.39/501100011033, and the European Union “Next GenerationEU/PRTR” (ECT2020-000827). J. Arribas is funded by the Breast Cancer Research Foundation (BCRF-23-008), Instituto de Salud Carlos III (project reference numbers AC15/00062, CB16/12/00449, and PI22/00001), and the European Commission under the framework of the ERA-NET TRANSCAN-2 initiative cofinanced by FEDER and Asociación Española Contra el Cáncer. A. Vivancos was the recipient of a project award from the FAECC (AVP/18/AECC/3219) and received funding from the Advanced Molecular Diagnostic (DIAMAV) program from the FERO Foundation (8361) and from ISDIN for supporting the development of liquid biopsy applications at the Cancer Genomics Lab (1848). M. Sansó was the recipient of a II FERO-GHD grant from the FERO Foundation (FERO/5086) and an investigator award from the FAECC (INVES19056SANS), and received funding from the Health Research Institute of the Balearic Islands (IdISBa), the RADIX-Janssen program (RADIX/JANSSEN21/01), and the Miguel Servet Program funded by the ISCIII (CP22/00131)
EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis:rationale, design, and study protocol of a large-scale epidemiological study in Europe
BACKGROUND: The growing prevalence of eosinophilic esophagitis (EoE) represents a considerable burden to patients and health care systems. Optimizing cost-effective management and identifying mechanisms for disease onset and progression are required. However, the paucity of large patient cohorts and heterogeneity of practice hinder the defining of optimal management of EoE. METHODS: EoE CONNECT is an ongoing, prospective registry study initiated in 2016 and currently managed by EUREOS, the European Consortium for Eosinophilic Diseases of the Gastrointestinal Tract. Patients are managed and treated by their responsible specialists independently. Data recorded using a web-based system include demographic and clinical variables; patient allergies; environmental, intrapartum, and early life exposures; and family background. Symptoms are structurally assessed at every visit; endoscopic features and histological findings are recorded for each examination. Prospective treatment data are registered sequentially, with new sequences created each time a different treatment (active principle, formulation, or dose) is administered to a patient. EoE CONNECT database is actively monitored to ensure the highest data accuracy and the highest scientific and ethical standards. RESULTS: EoE CONNECT is currently being conducted at 39 centers in Europe and enrolls patients of all ages with EoE. In its aim to increase knowledge, to date EoE CONNECT has provided evidence on the effectiveness of first- and second-line therapies for EoE in clinical practice, the ability of proton pump inhibitors to induce disease remission, and factors associated with improved response. Drug effects to reverse fibrous remodeling and endoscopic features of fibrosis in EoE have also been assessed. CONCLUSION: This prospective registry study will provide important information on the epidemiological and clinical aspects of EoE and evidence as to the real-world and long-term effectiveness and safety of therapy. These data will potentially be a vital benchmark for planning future EoE health care services in Europe
- …